Paricalcitol is an active Vitamin D2 analog for the Pharmaceutical industry. Paricalcitol is used for the treatment and prevention of secondary hyperparathyroidism associated with chronic kidney disease (CKD). It has been shown to reduce parathyroid hormone levels by inhibiting its synthesis and secretion.

CARBOGEN AMCIS manufactures this API under cGMP regime at its HIPO manufacturing facilities in Veenendaal, the Netherlands.

**Specification:**
- Chemical name: Paricalcitol; 19-NOR-1α,25-dihydroxyergocalciferol; 19-NOR-1α,25-dihydroxy D2 Content Paricalcitol (HPLC) is 97.0-103.0%
- CAS 131918-61-1

**Structural formula:**

![Structural formula image]

**CAS no.** 131918-61-1

**Toxic classification:** Very toxic (category T+). Before handling this substance, read the special directions on the label and Safety Data Sheet (available upon request).

**Regulatory:** DMF available. An ASMF has been filed and accepted in several European countries.

**Application:** Pharmaceutical industry. Suitable for drug formulation including tablets, injectables, oral solutions and soft gel capsules.